STOCK TITAN

ImmunoGen, Inc. - $IMGN STOCK NEWS

Welcome to our dedicated page for ImmunoGen news (Ticker: $IMGN), a resource for investors and traders seeking the latest updates and insights on ImmunoGen stock.

ImmunoGen, Inc. (NASDAQ: IMGN) is a pioneering clinical-stage biotechnology company focused on developing targeted anticancer therapeutics using proprietary antibody-drug conjugate (ADC) technology. The company's mission is to create groundbreaking treatments that improve outcomes for cancer patients.

ImmunoGen's flagship product, ELAHERE® (mirvetuximab soravtansine-gynx), is a first-in-class ADC that has received accelerated approval from the U.S. FDA for treating adult patients with folate receptor alpha (FRα) positive, platinum-resistant ovarian cancer. This innovative therapy is the first targeted medicine to demonstrate a meaningful survival benefit in this patient group.

Recent News: On November 30, 2023, AbbVie Inc. (NYSE: ABBV) and ImmunoGen announced a definitive agreement under which AbbVie will acquire ImmunoGen for $31.26 per share in cash. This acquisition, valued at approximately $10.1 billion, is expected to close in mid-2024, pending shareholder and regulatory approvals.

ImmunoGen has a robust pipeline of next-generation ADCs, including IMGN-151, designed for ovarian cancer, and Pivekimab sunirine, targeting rare blood cancer BPDCN. The company's technology is also utilized in Roche's marketed product, Kadcyla, highlighting its industry-wide impact.

With its innovative approaches and strategic partnerships, ImmunoGen is at the forefront of developing cutting-edge cancer therapies aimed at disrupting the progression of cancer and offering patients more good days.

  • Lead Product: ELAHERE® for platinum-resistant ovarian cancer
  • Pipeline Products: IMGN-151, Pivekimab sunirine
  • Partnerships: Roche, AbbVie
  • Technology: Proprietary antibody-drug conjugate (ADC) technology
  • Financial Condition: Recently valued at $10.1 billion in acquisition deal with AbbVie
  • Website: www.immunogen.com
Rhea-AI Summary
ImmunoGen's Marketing Authorization Application for mirvetuximab soravtansine accepted by the EMA for the treatment of platinum-resistant ovarian cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
ImmunoGen Inc. to host conference call to discuss third quarter 2023 operating results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
-
Rhea-AI Summary
ImmunoGen approves grants of stock options and RSUs to new employees under the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ImmunoGen Inc. announces findings from Phase 3 trial of ELAHERE in patients with FRα-positive platinum-resistant ovarian cancer, showing improvements in progression-free survival, objective response rates, and overall survival compared to chemotherapy. The benefit seen with ELAHERE in patients treated with a prior PARP inhibitor is particularly encouraging. ELAHERE demonstrates a tolerable safety profile. The company plans to submit applications to regulatory authorities for approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
ImmunoGen grants non-qualified stock options and restricted stock units to new CFO Lauren White
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary
ImmunoGen appoints Lauren White as Senior Vice President and Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
Rhea-AI Summary
ImmunoGen, Inc. approves grants of stock options and RSUs to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
ImmunoGen enters exclusive collaboration with Takeda to develop and commercialize ELAHERE in Japan, receiving $34 million upfront and milestone payments, as well as double-digit royalties on future net sales in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
Rhea-AI Summary
IMGN: ImmunoGen Announces Departure of Chief Medical Officer and Successor Appointment. Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down to pursue new opportunities outside of ImmunoGen. Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer. The announcement highlights Dr. Berkenblit's significant contributions to ImmunoGen's pivotal development program for ELAHERE (mirvetuximab soravtansine-gynx) and the accelerated approval for patients with platinum-resistant ovarian cancer. The press release also emphasizes the company's continued advancement of their clinical pipeline of next-generation ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
none

FAQ

What does ImmunoGen, Inc. specialize in?

ImmunoGen, Inc. specializes in developing targeted anticancer therapeutics using proprietary antibody-drug conjugate (ADC) technology.

What is ELAHERE®?

ELAHERE® (mirvetuximab soravtansine-gynx) is ImmunoGen's lead product, a first-in-class ADC approved for treating FRα positive, platinum-resistant ovarian cancer.

Who is acquiring ImmunoGen, Inc.?

AbbVie Inc. is acquiring ImmunoGen, Inc. in a deal valued at approximately $10.1 billion.

What is the significance of the acquisition by AbbVie?

The acquisition expands AbbVie's oncology portfolio with ImmunoGen's innovative ADC technology and products, accelerating its presence in the solid tumor space.

What other products are in ImmunoGen's pipeline?

ImmunoGen's pipeline includes IMGN-151 for ovarian cancer and Pivekimab sunirine targeting BPDCN, a rare blood cancer.

What technology does ImmunoGen use?

ImmunoGen uses proprietary antibody-drug conjugate (ADC) technology to create targeted cancer therapies.

What is Kadcyla?

Kadcyla is a marketed product by Roche that utilizes ImmunoGen's ADC technology for cancer treatment.

When is the acquisition by AbbVie expected to close?

The acquisition is expected to close in mid-2024, subject to shareholder and regulatory approvals.

Where can I find more information about ImmunoGen, Inc.?

More information can be found on ImmunoGen's official website at www.immunogen.com.

What is the focus of ImmunoGen's research and development?

ImmunoGen focuses on developing next-generation ADCs to improve cancer treatment outcomes by generating therapies with enhanced anti-tumor activity and favorable tolerability profiles.

ImmunoGen, Inc.

Nasdaq:IMGN

IMGN Rankings

IMGN Stock Data

8.72B
247.85M
0.32%
86.52%
7.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston